10.25384/SAGE.C.6430702
Andrea Dennis
Andrea
Dennis
Daniel J Cuthbertson
Daniel J
Cuthbertson
Dan Wootton
Dan
Wootton
Michael Crooks
Michael
Crooks
Mark Gabbay
Mark
Gabbay
Nicole Eichert
Nicole
Eichert
Sofia Mouchti
Sofia
Mouchti
Michele Pansini
Michele
Pansini
Adriana Roca-Fernandez
Adriana
Roca-Fernandez
Helena Thomaides-Brears
Helena
Thomaides-Brears
Matt Kelly
Matt
Kelly
Matthew Robson
Matthew
Robson
Lyth Hishmeh
Lyth
Hishmeh
Emily Attree
Emily
Attree
Melissa Heightman
Melissa
Heightman
Rajarshi Banerjee
Rajarshi
Banerjee
Amitava Banerjee
Amitava
Banerjee
Multi-organ impairment and long COVID: a 1-year prospective, longitudinal cohort study
<div>Objectives<p>To determine the prevalence of organ impairment in long COVID patients at 6 and 12 months after initial symptoms and to explore links to clinical presentation.</p>Design<p>Prospective cohort study.</p>Participants<p>Individuals.</p>Methods<p>In individuals recovered from acute COVID-19, we assessed symptoms, health status, and multi-organ tissue characterisation and function.</p>Setting<p>Two non-acute healthcare settings (Oxford and London). Physiological and biochemical investigations were performed at baseline on all individuals, and those with organ impairment were reassessed.</p>Main outcome measures<p>Primary outcome was prevalence of single- and multi-organ impairment at 6 and 12 months post COVID-19.</p>Results<p>A total of 536 individuals (mean age 45 years, 73% female, 89% white, 32% healthcare workers, 13% acute COVID-19 hospitalisation) completed baseline assessment (median: 6 months post COVID-19); 331 (62%) with organ impairment or incidental findings had follow-up, with reduced symptom burden from baseline (median number of symptoms 10 and 3, at 6 and 12 months, respectively). Extreme breathlessness (38% and 30%), cognitive dysfunction (48% and 38%) and poor health-related quality of life (EQ-5D-5Lā<ā0.7; 57% and 45%) were common at 6 and 12 months, and associated with female gender, younger age and single-organ impairment. Single- and multi-organ impairment were present in 69% and 23% at baseline, persisting in 59% and 27% at follow-up, respectively.</p>Conclusions<p>Organ impairment persisted in 59% of 331 individuals followed up at 1 year post COVID-19, with implications for symptoms, quality of life and longer-term health, signalling the need for prevention and integrated care of long COVID.</p><p>Trial Registration: ClinicalTrials.gov Identifier: NCT04369807</p></div>
Medicine
SAGE Journals
2023
2023-02-15
2023-02-15
Collection
CC BY 4.0